Table 4 Risk factors for mortality in infants with NRF

Higher gestational age

0.92(0.89, 0.94)

0.89(0.82, 0.96)

Higher BW

1.00(1.00, 1.00)

1.00(0.99, 1.00)

Congenital anomalies

5.63(3.69, 8.58)

8.54(5.03, 14.49)

Cesarean delivery

0.62(0.51, 0.75)

0.73(0.57, 0.94)

Higher Apgar score at 1 min

0.75(0.72, 0.78)

0.85(0.78, 0.94)

HIE

2.85(1.91, 4.25)

2.48(1.35, 4.56)

Non-invasive respiratory support only

0.15(0.12, 0.19)

0.40(0.29, 0.57)

Invasive respiratory support only

9.18(7.51, 11.21)

6.85(5.01, 9.36)

PS

1.61(1.33, 1.95)

0.80(0.61, 1.06)

iNO therapy

6.49(4.59, 9.17)

3.81(2.24, 6.49)

Caffeine therapy

1.09(0.93, 1.33)

0.68(0.50, 0.94)

Subgroup analysis(< 32 weeks or < 1500 g at birth)

 Higher gestational age

0.63(0.59, 0.68)

0.82(0.75, 0.93)

 Higher BW

0.99(0.99, 0.99)

0.99(0.99, 0.99)

 Congenital anomalies

4.85(2.40, 9.82)

7.84(3.38, 18.17)

 Higher Apgar score at 1 min

0.74(0.70, 0.78)

0.86(0.77, 0.96)

 Invasive respiratory support only

16.33(11.88, 22.44)

8.83(5.83, 13.87)

 PS

2.18(1.66, 2.86)

0.82(0.56, 1.19)

 iNO therapy

9.57(4.85, 18.85)

5.84(2.51, 13.62)

 Caffeine therapy

0.63(0.48, 0.83)

0.44(0.31, 0.63)

Subgroup analysis( ≥ 32 weeks and ≥ 1500 g at birth)

 Congenital anomalies

7.08(4.15, 12.08)

8.66(4.00, 18.75)

 Non-invasive respiratory support only

0.12(0.87, 1.81)

0.41(0.22, 0.74)

 Invasive respiratory support only

9.82(7.29, 13.22)

4.25(2.56, 7.06)

 iNO therapy

7.29(4.77, 11.13)

2.19(1.05, 4.54)